Global Anti-Peptic Ulcer Drugs Market Growth (Status and Outlook) 2025-2031

Global Anti-Peptic Ulcer Drugs Market Growth (Status and Outlook) 2025-2031

The global Anti-Peptic Ulcer Drugs market size is predicted to grow from US$ 10940 million in 2025 to US$ 23890 million in 2031; it is expected to grow at a CAGR of 13.9% from 2025 to 2031.

Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.

Global Anti-Peptic Ulcer Drugs key players include AstraZeneca, Ask-pharm, Takeda, Yangtze River Pharm, Shandong Luoxin, etc. Global top five players hold a share about 50%.

In terms of product, the segment includes Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs. And in terms of application, the application includes Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD).

LPI (LP Information)' newest research report, the “Anti-Peptic Ulcer Drugs Industry Forecast” looks at past sales and reviews total world Anti-Peptic Ulcer Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Anti-Peptic Ulcer Drugs sales for 2025 through 2031. With Anti-Peptic Ulcer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Peptic Ulcer Drugs industry.

This Insight Report provides a comprehensive analysis of the global Anti-Peptic Ulcer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Anti-Peptic Ulcer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-Peptic Ulcer Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Peptic Ulcer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Peptic Ulcer Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Peptic Ulcer Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Proton Pump Inhibitors (PPIs)
Potassium-Competitive Acid Blockers (P-CAB)
Antacids
H2 Antagonists
Ulcer Protective Drugs

Segmentation by Application:
Gastritis
Gastric Ulcers
Duodenal Ulcers
Gastroesophageal Reflux Disease (GERD)

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Ask-pharm
Takeda
Yangtze River Pharm
Shandong Luoxin
Huadong Medicine
Changzhou Siyao
Beijing Yuekang
Guangdong Dahua
Xian Janssen

Please note: The report will take approximately 2 business days to prepare and deliver.